Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Elanco to become No. 2 in animal health with $7.6 billion Bayer deal

Elanco Animal Health agreed to buy Bayer’s veterinary drugs unit in a cash and stock deal valued at $7.6 billion, creating the second-largest maker of medicines for pets and livestock and expanding Elanco’s reach online.

Read More »

Novo Nordisk’s new diabetes, obesity drugs lift sales outlook

Novo Nordisk’s sales forecast for 2019 was raised due to growing demand for obesity products and a new injectable treatment for diabetes, which is now the company’s growth engine as insulin sales decline.

Read More »

Sarepta says adverse event report for DMD gene therapy erroneously submitted

Sarepta Therapeutics Inc. was informed that an adverse event report was erroneously submitted to the U.S. health regulator regarding an ongoing study of the company’s gene therapy for Duchenne muscular dystrophy (DMD).

Read More »

Israel’s Teva Pharm profit falls less than expected, CFO to leave

Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter 2019 profit and said the chief financial officer was leaving the company.

Read More »

Sanofi Reports Strong Second-Quarter 2019

Sanofi reported overall net sales increased by 5.5 percent for second-quarter 2019, driven by Sanofi Genzyme, Sanofi Pasteur and emerging markets.

Read More »

AbbVie Raises 2019 Profit Target

Despite concerns about potential competition from recently approved and available European biosimilars to Humira, AbbVie was able to stave off some of the losses expected during Q2 2019.

Read More »

Bayer in frame to win first EU nod for high-precision cancer drug

The EMA recommended approving Vitrakvi to tackle tumors with a specific genetic mutation regardless of where the disease started.

Read More »

European panel clears GW Pharma cannabis drug

GW Pharmaceuticals’ marijuana-based treatment Epidyolex won a positive recommendation for marketing approval from a European Medicines Agency (EMA) panel for use as an additional treatment for two types of seizures.

Read More »

AstraZeneca raises 2019 sales forecast after second-quarter cancer drug, China boost

AstraZeneca Plc raised the company’s product sales forecast for 2019 after second-quarter results beat analysts’ expectations, thanks to strong sales from cancer medicines and emerging markets, especially China.

Read More »

Freenome Secures $160 Million to Advance Cancer Detection Blood Test

Freenome snagged $160 million in Series B financing to support the development of the company’s early cancer detection blood test.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!

Subscribe

Ad Right Bottom